Causality Assessment in Drug-Induced Liver Injury

被引:40
作者
Hayashi, Paul H. [1 ]
机构
[1] Univ N Carolina, Dept Med, Div Gastroenterol & Hepatol, UNC Liver Program, Chapel Hill, NC 27599 USA
关键词
Hepatotoxicity; dietary supplements; expert opinion; adverse drug reactions; ADVERSE-REACTIONS; CONSENSUS MEETINGS; PROBABILITY; AGREEMENT; SCALE; HYPERSENSITIVITY; ASSOCIATION; VALIDATION; DIAGNOSIS; CRITERIA;
D O I
10.1055/s-0029-1240003
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Assigning causality in drug-induced liver injury (DILI) due to a particular medication or herbal and dietary supplement relies on clinical history, exclusion of competing causes, prior reports of DILI, and judgment-no objective laboratory or histological tests exist to confirm a diagnosis of suspected DILI. Current causality assessment instruments are based on algorithmic scoring systems but are not widely used. Expert opinion remains the gold standard, but is cumbersome and has limited reproducibility. The lack of a valid and widely available causality assessment method hinders the identification of genetic and biochemical markers that may help better define DILI. Emerging technologies in pharmacogenomics and toxicogenomics may identify such markers if well-defined DILI cases and controls can provide tissue samples for analysis. In this article, current causality assessment instruments, including expert opinion, are discussed, and the necessary features for an improved instrument are provided.
引用
收藏
页码:348 / 356
页数:9
相关论文
共 42 条
[1]   Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions [J].
Aithal, GP ;
Rawlins, MD ;
Day, CP .
JOURNAL OF HEPATOLOGY, 2000, 33 (06) :949-952
[2]  
Andrade R. J., 1997, Journal of Hepatology, V26, P297
[3]   A new method for assessing drug causation provided agreement with experts' judgment [J].
Arimone, Y ;
Bégaud, B ;
Miremont-Salamé, G ;
Fourrier-Réglat, A ;
Molimard, M ;
Moore, N ;
Haramburu, F .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2006, 59 (03) :308-314
[4]   Agreement of expert judgment in causality assessment of adverse drug reactions [J].
Arimone, Y ;
Bégaud, B ;
Miremont-Salamé, G ;
Fourrier-Réglat, A ;
Moore, N ;
Molimard, M ;
Haramburu, F .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (03) :169-173
[5]   Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions [J].
Arimone, Yannick ;
Miremont-Salame, Ghada ;
Haramburu, Francoise ;
Molimard, Mathieu ;
Moore, Nicholas ;
Fourrier-Reglat, Annie ;
Begaud, Bernard .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 64 (04) :482-488
[6]  
BALISTRERI WF, 2008, NIH WORKSH DRUG IND, P25
[7]   CAUSALITY ASSESSMENT OF ADVERSE REACTIONS TO DRUGS .2. AN ORIGINAL MODEL FOR VALIDATION OF DRUG CAUSALITY ASSESSMENT METHODS - CASE-REPORTS WITH POSITIVE RECHALLENGE [J].
BENICHOU, C ;
DANAN, G ;
FLAHAULT, A .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1993, 46 (11) :1331-1336
[8]  
BENICHOU C, 1990, J HEPATOL, V11, P272
[9]   Drug-induced liver injury: Mechanisms and test systems [J].
Bissell, DM ;
Gores, GJ ;
Laskin, DL ;
Hoofnagle, JH .
HEPATOLOGY, 2001, 33 (04) :1009-+
[10]   Telithromycin-Associated Hepatotoxicity: Clinical Spectrum and Causality Assessment of 42 Cases [J].
Brinker, Allen D. ;
Wassel, Ronald T. ;
Lyndly, Jenna ;
Serrano, Jose ;
Avigan, Mark ;
Lee, William M. ;
Seeff, Leonard B. .
HEPATOLOGY, 2009, 49 (01) :250-257